GSK's licensing of LimmaTech Biologics to develop and commercialize a Shigella vaccine could potentially increase its revenues if the vaccine is successful. This is because GSK would likely receive royalties or other forms of payment from LimmaTech for the use of its license. However, the impact on GSK's stock price would depend on the success of the vaccine and the terms of the licensing agreement.